How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,947 results for

Desquamation

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Efficacy of heparinoid moisturizer as a prophylactic agent for radiation dermatitis following radiotherapy after breast-conserving surgery: a randomized controlled trial (PubMed)

Efficacy of heparinoid moisturizer as a prophylactic agent for radiation dermatitis following radiotherapy after breast-conserving surgery: a randomized controlled trial The application of heparinoid moisturizer for 2 weeks following whole-breast radiotherapy (WBRT) was previously reported to significantly increase skin water content (WC) and help improve skin dryness and desquamation. The prospective open-label, randomized trial included an exploratory arm to investigate the preventive (...) following WBRT. Signs and symptoms were also assessed.Comparing two groups, WC values were significantly higher in group P until 4 weeks following WBRT. At 2 weeks following WBRT, mean WC values in group P and C were 38.5 ± 6.1 arbitrary units (a.u.) and 30.2 ± 7.8 a.u., respectively (P < 0.001). In group C, dryness was more severe at 2 and 4 weeks following WBRT and desquamation more severe until 3 months following WBRT. However, the erythema score showed no difference between the two groups. Regarding

Full Text available with Trip Pro

2018 Japanese journal of clinical oncology

182. Proton Partial Breast Irradiation: Detailed Description of Acute Clinico-Radiologic Effects (PubMed)

<50% of the treated skin (60%). At six weeks most patients had either patchy erythema involving <50% of the overlying skin (33%) or patchy erythema involving >50% of the treated skin (28%). Only one patient developed any moist desquamation. At six months most patients had no visible skin changes (57%) or a small, circular area of mild hyperpigmentation (33%). Mammographic changes seen at six months were regional skin thickening (40%), residual seroma (14%), localized retraction (26%), and fat

Full Text available with Trip Pro

2018 Cancers

183. Radiation Recall Dermatitis in Patients Treated with Sorafenib (PubMed)

with palliative radiation therapy (RT) to a painful metastatic hepatocellular carcinoma lesion in the right forearm. He completed his radiation course with grade 1 dermatitis, which had resolved by the time he was started on sorafenib 400 mg twice daily 7 days afterwards. On the 21st day after RT, he presented with desquamation and erythema in the previously irradiated area of the right forearm, consistent with RRD. The sorafenib was discontinued and his symptoms subsequently resolved with conservative

Full Text available with Trip Pro

2018 Case reports in oncological medicine

184. Outcomes of ureteroscopy miniaturization on tissue damage and tissue hypoxia in a pig model (PubMed)

with hematoxylin-eosin revealed greater epithelial desquamation in the URS group (p < 0.05). Pimonidazole staining revealed greater hypoxia in the epithelial cells than in the remainder of the ureteral layers. We conclude that m-URS causes less damage to the ureteral orifice than URS. Histopathological findings show m-URS reduces ureteral epithelial damage compared with conventional ureteroscopy. Both URS and m-URS cause cellular hypoxia.

Full Text available with Trip Pro

2018 Scientific reports

185. Interest of Supportive and Barrier Protective Skin Care Products in the Daily Prevention and Treatment of Cutaneous Toxicity During Radiotherapy for Breast Cancer (PubMed)

, prospective study evaluated the tolerability and benefit of supportive and barrier protective skin care products in preventing radiotherapy-induced skin reactions in 253 women initiating radiotherapy (exclusive or adjuvant) for breast cancer.Patients received a kit of 5 commercially available skin care products before the first radiotherapy treatment. The following variables were assessed: cutaneous adverse events, investigator-assessed skin reactions (oedema, erythema, dryness, desquamation) before

Full Text available with Trip Pro

2018 Breast cancer : basic and clinical research

186. Cutaneous Toxicity in a Laboratory Beagle (Canis lupus familiaris) after Chronic Administration of Doxorubicin Hydrochloride (PubMed)

Cutaneous Toxicity in a Laboratory Beagle (Canis lupus familiaris) after Chronic Administration of Doxorubicin Hydrochloride An adult female beagle (Canis lupus familiaris) used in a model of doxorubicin-induced cardiomyopathy presented with epithelial desquamation on the shoulders and ventrum after receiving the 8th weekly intravenous dose of the free form of doxorubicin (20 mg/m2; total accumulation, 160 mg/m2). The lesions were empirically treated with topical disinfectants and topical

Full Text available with Trip Pro

2018 Comparative medicine

187. Fossilized skin reveals coevolution with feathers and metabolism in feathered dinosaurs and early birds (PubMed)

-avian maniraptoran dinosaurs and a basal bird from the Cretaceous Jehol biota (China). The skin comprises patches of desquamating epidermal corneocytes that preserve a cytoskeletal array of helically coiled α-keratin tonofibrils. This structure confirms that basal birds and non-avian dinosaurs shed small epidermal flakes as in modern mammals and birds, but structural differences imply that these Cretaceous taxa had lower body heat production than modern birds. Feathered epidermis acquired many

Full Text available with Trip Pro

2018 Nature communications

188. Case series of docetaxel-induced dorsal hand–foot syndrome (PubMed)

Case series of docetaxel-induced dorsal hand–foot syndrome Palmar-plantar erythrodysesthesia, also known as hand-foot syndrome (HFS), is a well-known dermatologic adverse event that can occur with a variety of cytotoxic chemotherapies including fluoropyrimidines, cytarabine, liposomal doxorubicin, and taxanes. HFS often presents as painful erythemas and desquamation of the skin involving the palms of the hands and the soles of the feet. Three cases are presented of patients with breast cancer

Full Text available with Trip Pro

2018 Therapeutic advances in drug safety

189. La miliaire cristalline généralisée: à propos d’un cas (PubMed)

spontaneously in a few hours giving rise to a desquamation, as occurred in our patient after regression of febrile syndrome.

Full Text available with Trip Pro

2018 The Pan African medical journal

190. Exfoliative Cheilitis as a Manifestation of Factitial Cheilitis (PubMed)

Exfoliative Cheilitis as a Manifestation of Factitial Cheilitis Factitial cheilitis is a rare diagnosis of exclusion that occurs most frequently in young women with a history of anxiety disorders and recent psychosocial stressors. It presents as continuous keratinaceous build-up, crusting, and desquamation of the lips, consistent with exfoliative cheilitis. Affected areas can progress to superinfection with Staphylococcus aureus or Candida albicans. We report a case of a 23-year-old woman who

Full Text available with Trip Pro

2018 Cureus

191. Methanol as an Unlisted Ingredient in Supposedly Alcohol-Based Hand Rub Can Pose Serious Health Risk (PubMed)

absorption resulting in chronic toxicity (e.g., visual disturbances) occurs, particularly if methanol induced desquamation and dermatitis are present. Nationwide surveillance systems, regional/international toxicovigilance networks and situational awareness among the healthcare professionals should facilitate the early detection, management and prevention of such poisoning incidents of public health significance.

Full Text available with Trip Pro

2018 International journal of environmental research and public health

192. Timing for Rectal Surgery After Chemoradiotherapy

toxicity scale: Skin Grade 1 follicular, faint or dull erythema / epilation / dry desquamation / decreased sweating; Grade 2 tender or bright erythema, patchy moist desquamation / moderate edema; Grade 3 confluent, moist desquamation other than skin folds, pitting edema; Grade 4 - ulceration, hemorrhage, necrosis Radiotherapy toxicity assessed by EORTC scale [ Time Frame: 5 years ] Radiotherapy related toxicity rates: gastrointestinal reactions will be assessed using EORTC radiotherapy toxicity scale

2018 Clinical Trials

193. Efficacy of the Cosmetic Product "Onco-Repair" on Grade 2 Hand Foot Syndrome

Erythrodysethesia, is a common adverse event observed in subjects under anti-tumor therapy with conventional chemotherapy or targeted thérapies. The initial symptoms are dysesthesia and tingling in the palms, fingers and soles of feet and erythema, which may progress to burning pain with dryness, cracking, desquamation, ulceration and oedema. Sensory impairment, paresthesia and pruritus have also been reported. Palms of the hands are more frequently affected than soles of the feet, and might even be the only

2018 Clinical Trials

194. Durapore vs. Hy-Tape to Secure The Endotracheal Tube

caused upon removal of the tape is the primary outcome of interest. Investigators will use a validated scale called the "National Academy of Science Classification System for contact dermatitis." Rating will be done independently by two dermatologists. Grade 0: No response, no edema, no erythema Grade 1/2: Questionable or faint, indistinct erythema (barely perceptible) or mild desquamation Grade 1: Well-defined erythema or desquamation Grade 2: Erythema with slight to moderate oedema (area raised

2018 Clinical Trials

195. A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Topical ESR-114 in Subjects With Plaque Psoriasis

, & Desquamation; score range: 0-12; lower score is better outcome) at Week 6 Secondary Outcome Measures : Proportion of subjects with clear or almost clear on the Physician Global Assessment [ Time Frame: 6 weeks ] Proportion of subjects with clear or almost clear on the Physician Global Assessment (PGA) at Week 6 Proportion of subjects with PASI75 [ Time Frame: 6 weeks ] Proportion of subjects with PASI75 at Week 6 Change from Baseline in erythema score over time [ Time Frame: 6 weeks ] Change from Baseline (...) in erythema score (score range: 0-4; lower score is better outcome) at Weeks 1, 2, 4, and 6 Change from Baseline in induration score over time [ Time Frame: 6 weeks ] Change from Baseline in induration score (score range: 0-4; lower score is better outcome) at Weeks 1, 2, 4, and 6 Change from Baseline in desquamation score over time [ Time Frame: 6 weeks ] Change from Baseline in desquamation score (score range: 0-4; lower score is better outcome) at Weeks 1, 2, 4, and 6 Eligibility Criteria Go

2018 Clinical Trials

196. IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry

at the first follow-up visit after IORT (4-6 weeks after treatment). Radiation dermatitis will be scored based upon CTCAE (Common Terminology Criteria for Adverse Events) v4.03 scale as follows: GRADE 1: Faint erythema or dry desquamation GRADE 2: Moderate to brisk erythema; patchy moist desquamation, mostly confined to skin folds and creases; moderate edema GRADE 3: Moist desquamation in areas other than skin folds and creases; bleeding induced by minor trauma or abrasion GRADE 4: Life threatening

2018 Clinical Trials

197. Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma

feeding females (lactating females must agree not to breast feed while taking lenalidomide). Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study. Use of any other experimental drug or therapy within 28 days of baseline. Known hypersensitivity to thalidomide. Known prior development of erythema nodosum if characterized by a desquamating rash

2018 Clinical Trials

198. Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color

) to 72 (maximal disease) Change in Psoriasis Scalp Severity Index [ Time Frame: baseline, 2 weeks, 4 weeks, 8 weeks ] Proportion of patients achieving ≥50% improvement and/or ≥75% improvement in PSSI at weeks 2, 4 and 8 compared to baseline if applicable. The Psoriasis Scalp Severity Index (PSSI) assesses severity of scalp disease along the parameters of erythema, induration, and desquamation. The PSSI uses a 5-point scale to grade the three aforementioned clinical parameters. The parameters scores

2018 Clinical Trials

199. Clinical, Radiological and Microbiological Outcomes of Implants With Two Different Connection Configurations, a Split-mouth RCT.

system. Unbalanced diabetes mellitus. (HbA1c above 6.5), Uncontrolled endocrine diseases Psychotic diseases. Hypersensitivity to one of the components of the implant in general and titanium in particular. Women who are pregnant or lactating. Lack of patient cooperation. Parafunctional habits, such as Bruxism or Temporomandibular joint disease. Various pathologies of the oral mucosa for example: Benign mucous pemphigoid, desquamative ginigivitis, erosive lichen planus, malignancy of oral cavity, bolus

2018 Clinical Trials

200. Immune Response and General Immune Health in Subjects Infected With Herpes Simplex Virus Type 1 (HSV-1)

hypopigmentation, a burning sensation after application, and systemic reactions including fever and arthralgias. A study completed by Oglio et al of eight patients treated with SADBE for warts noted only mild and well tolerated side effects of erythema, desquamation, cutaneous edema, pruritus, burning, and pain. SADBE induces a delayed-type hypersensitivity response which in warts, is believed to induce the killing of virally infected cells by cytotoxic lymphocytes. This influx of lymphocytes into lesional

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>